FDA Approval in Germline BRCA-Mutated, HER2-Negative, High-Risk Early Breast Cancer

In this week's episode, we'll discuss a recent FDA approval in germline BRCA-mutated, HER2-negative, high-risk early breast cancer. Then, we'll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.